Literature DB >> 29614432

Pathological significance of lipoprotein(a) in aortic valve stenosis.

Bin Yu1, Kashif Khan1, Qutayba Hamid2, Ahmad Mardini1, Ateeque Siddique1, Louis Philippe Aguilar-Gonzalez1, Georges Makhoul1, Hossny Alaws1, Jacques Genest1, George Thanassoulis1, Renzo Cecere1, Adel Schwertani3.   

Abstract

BACKGROUND AND AIMS: Aortic valve stenosis (AVS) affects a significant percentage of our elderly population and younger subjects with familial hypercholesterolemia. Lipoprotein(a) [Lp(a)] has been associated with AVS in recent genetic studies. The purpose of this study was to determine the effects of Lp(a) on human aortic valve interstitial cells (HAVICs), and to identify apolipoproteins and phospholipids in diseased human aortic valves.
METHODS: We examined the effects of Lp(a) on HAVICs mineralization and oxidant formation. Proteomic analyses were used to determine the effects of Lp(a) on downstream intracellular markers. We also used mass spectroscopy to identify the different lipoproteins and oxidized phospholipids in calcified aortic valves.
RESULTS: HAVICs incubated with either LDL or Lp(a) had significantly higher calcium deposition, compared to control (p<0.001), with Lp(a) having the most significant effect (p<0.01) compared to LDL. Proteomic analysis after 10 days of treatment with Lp(a) resulted in enrichment of proteins involved in calcium deposition and vesicle biogenesis. Treatment of HAVICs with Lp(a) significantly increased ROS formation (p<0.05). Patients with calcific aortic stenosis had higher plasma Lp(a) concentrations compared to non-CAD individuals (p<0.001). LC-MS/MS revealed the presence of apolipoproteins and phospholipids in calcified human aortic valves.
CONCLUSIONS: The present study outlines an association between Lp(a) and AVS, and suggests that Lp(a) may serve as a potential target for therapeutic purposes to manage the progression of AVS.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Aortic valve stenosis; Calcium; ELISA; Human; MS/MS; Oxidant formation; Oxidized phospholipids

Mesh:

Substances:

Year:  2018        PMID: 29614432     DOI: 10.1016/j.atherosclerosis.2018.03.025

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  10 in total

Review 1.  Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?

Authors:  Željko Reiner
Journal:  Curr Atheroscler Rep       Date:  2019-03-07       Impact factor: 5.113

Review 2.  Calcific Aortic Valve Stenosis and Atherosclerotic Calcification.

Authors:  Michel Pompeu Barros de Oliveira Sá; Luiz Rafael P Cavalcanti; Álvaro M Perazzo; Rafael A F Gomes; Marie-Annick Clavel; Philippe Pibarot; Giuseppe Biondi-Zoccai; Konstantin Zhigalov; Alexander Weymann; Arjang Ruhparwar; Ricardo Carvalho Lima
Journal:  Curr Atheroscler Rep       Date:  2020-01-07       Impact factor: 5.113

3.  Association Between Lipoprotein(a) and Calcific Aortic Valve Disease: A Systematic Review and Meta-Analysis.

Authors:  Qiyu Liu; Yanqiao Yu; Ruixi Xi; Jingen Li; Runmin Lai; Tongxin Wang; Yixuan Fan; Zihao Zhang; Hao Xu; Jianqing Ju
Journal:  Front Cardiovasc Med       Date:  2022-04-25

Review 4.  Role of oxidative stress in calcific aortic valve disease and its therapeutic implications.

Authors:  Harry Z E Greenberg; Guoan Zhao; Ajay M Shah; Min Zhang
Journal:  Cardiovasc Res       Date:  2022-05-06       Impact factor: 13.081

5.  Plasma and urine metabolomic analyses in aortic valve stenosis reveal shared and biofluid-specific changes in metabolite levels.

Authors:  Cynthia Al Hageh; Ryan Rahy; Georges Khazen; Francois Brial; Rony S Khnayzer; Dominique Gauguier; Pierre A Zalloua
Journal:  PLoS One       Date:  2020-11-25       Impact factor: 3.240

Review 6.  Aortic Valve Stenosis and Mitochondrial Dysfunctions: Clinical and Molecular Perspectives.

Authors:  Gaia Pedriali; Giampaolo Morciano; Simone Patergnani; Paolo Cimaglia; Cristina Morelli; Elisa Mikus; Roberto Ferrari; Vincenzo Gasbarro; Carlotta Giorgi; Mariusz R Wieckowski; Paolo Pinton
Journal:  Int J Mol Sci       Date:  2020-07-11       Impact factor: 5.923

Review 7.  Models and Techniques to Study Aortic Valve Calcification in Vitro, ex Vivo and in Vivo. An Overview.

Authors:  Maria Bogdanova; Arsenii Zabirnyk; Anna Malashicheva; Daria Semenova; John-Peder Escobar Kvitting; Mari-Liis Kaljusto; Maria Del Mar Perez; Anna Kostareva; Kåre-Olav Stensløkken; Gareth J Sullivan; Arkady Rutkovskiy; Jarle Vaage
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

Review 8.  The mechanistic pathways of oxidative stress in aortic stenosis and clinical implications.

Authors:  Kailun Phua; Nicholas Ws Chew; William Kf Kong; Ru-San Tan; Lei Ye; Kian-Keong Poh
Journal:  Theranostics       Date:  2022-07-04       Impact factor: 11.600

9.  Association of serum lipoprotein(a) level with the severity and prognosis of calcific aortic valve stenosis: a Chinese cohort study.

Authors:  Shuo-Lin Liu; Rynat Rozi; Hui-Wei Shi; Ying Gao; Yuan-Lin Guo; Yi-Da Tang; Jian-Jun Li; Na-Qiong Wu
Journal:  J Geriatr Cardiol       Date:  2020-03       Impact factor: 3.327

Review 10.  Patient Management in Aortic Stenosis: Towards Precision Medicine Through Protein Analysis, Imaging and Diagnostic Tests.

Authors:  Laura Mourino-Alvarez; Tatiana Martin-Rojas; Cecilia Corros-Vicente; Nerea Corbacho-Alonso; Luis R Padial; Jorge Solis; María G Barderas
Journal:  J Clin Med       Date:  2020-07-28       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.